| SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN) VJ Hall, S Foulkes, A Charlett, A Atti, EJM Monk, R Simmons, E Wellington, ... The Lancet 397 (10283), 1459-1469, 2021 | 820* | 2021 |
| COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study VJ Hall, S Foulkes, A Saei, N Andrews, B Oguti, A Charlett, E Wellington, ... The Lancet 397 (10286), 1725-1735, 2021 | 759 | 2021 |
| Spike-antibody waning after second dose of BNT162b2 or ChAdOx1 M Shrotri, AMD Navaratnam, V Nguyen, T Byrne, C Geismar, E Fragaszy, ... The Lancet 398 (10298), 385-387, 2021 | 428 | 2021 |
| Antibody response to SARS-CoV-2 infection in humans: A systematic review N Post, D Eddy, C Huntley, MCI Van Schalkwyk, M Shrotri, D Leeman, ... PloS one 15 (12), e0244126, 2020 | 399 | 2020 |
| Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a … M Shrotri, M Krutikov, T Palmer, R Giddings, B Azmi, S Subbarao, C Fuller, ... The Lancet Infectious Diseases 21 (11), 1529-1538, 2021 | 202 | 2021 |
| An interactive website tracking COVID-19 vaccine development M Shrotri, T Swinnen, B Kampmann, EPK Parker The Lancet Global Health 9 (5), e590-e592, 2021 | 154 | 2021 |
| T cell response to SARS-CoV-2 infection in humans: A systematic review M Shrotri, MCI van Schalkwyk, N Post, D Eddy, C Huntley, D Leeman, ... PloS one 16 (1), e0245532, 2021 | 140 | 2021 |
| Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibodies in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study … M Krutikov, T Palmer, G Tut, C Fuller, B Azmi, R Giddings, M Shrotri, ... The Lancet Healthy Longevity 3 (1), e13-e21, 2022 | 93 | 2022 |
| Prevalence and characteristics of persistent symptoms in children during the COVID-19 pandemic: evidence from a household cohort study in England and Wales F Miller, V Nguyen, AMD Navaratnam, M Shrotri, J Kovar, AC Hayward, ... The Pediatric infectious disease journal 41 (12), 979-984, 2022 | 87 | 2022 |
| Clinical characteristics and outcomes in patients with COVID-19 and cancer: a systematic review and meta-analysis P Zarifkar, A Kamath, C Robinson, N Morgulchik, SFH Shah, TKM Cheng, ... Clinical Oncology 33 (3), e180-e191, 2021 | 77 | 2021 |
| Incidence of SARS-CoV-2 infection according to baseline antibody status in staff and residents of 100 long-term care facilities (VIVALDI): a prospective cohort study M Krutikov, T Palmer, G Tut, C Fuller, M Shrotri, H Williams, D Davies, ... The Lancet Healthy Longevity 2 (6), e362-e370, 2021 | 69 | 2021 |
| Keeping track of the SARS-CoV-2 vaccine pipeline EPK Parker, M Shrotri, B Kampmann Nature Reviews Immunology 20 (11), 650-650, 2020 | 69 | 2020 |
| Risk factors, symptom reporting, healthcare-seeking behaviour and adherence to public health guidance: protocol for Virus Watch, a prospective community cohort study A Hayward, E Fragaszy, J Kovar, V Nguyen, S Beale, T Byrne, A Aryee, ... BMJ open 11 (6), e048042, 2021 | 55 | 2021 |
| Profile of humoral and cellular immune responses to single doses of BNT162b2 or ChAdOx1 nCoV-19 vaccines in residents and staff within residential care homes (VIVALDI): an … G Tut, T Lancaster, M Krutikov, P Sylla, D Bone, N Kaur, E Spalkova, ... The Lancet Healthy Longevity 2 (9), e544-e553, 2021 | 53 | 2021 |
| Outcomes of SARS-CoV-2 omicron infection in residents of long-term care facilities in England (VIVALDI): a prospective, cohort study M Krutikov, O Stirrup, H Nacer-Laidi, B Azmi, C Fuller, G Tut, T Palmer, ... The Lancet Healthy longevity 3 (5), e347-e355, 2022 | 45 | 2022 |
| SARS-CoV-2 antibodies and breakthrough infections in the Virus Watch cohort RW Aldridge, A Yavlinsky, V Nguyen, MT Eyre, M Shrotri, ... Nature Communications 13 (1), 4869, 2022 | 40 | 2022 |
| Waning of SARS-CoV-2 antibodies targeting the Spike protein in individuals post second dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and risk of breakthrough infections … RW Aldridge, A Yavlinsky, V Nguyen, MT Eyre, M Shrotri, ... MedRxiv, 2021.11. 05.21265968, 2021 | 39 | 2021 |
| Occupation, work-related contact and SARS-CoV-2 anti-nucleocapsid serological status: findings from the Virus Watch prospective cohort study S Beale, P Patel, A Rodger, I Braithwaite, T Byrne, WLE Fong, E Fragaszy, ... Occupational and Environmental Medicine 79 (11), 729-735, 2022 | 36 | 2022 |
| Duration of vaccine effectiveness against SARS-CoV-2 infection, hospitalisation, and death in residents and staff of long-term care facilities in England (VIVALDI): a … M Shrotri, M Krutikov, H Nacer-Laidi, B Azmi, T Palmer, R Giddings, ... The Lancet Healthy Longevity 3 (7), e470-e480, 2022 | 34 | 2022 |
| Nucleocapsid and spike antibody responses following virologically confirmed SARS-CoV-2 infection: an observational analysis in the Virus Watch community cohort AMD Navaratnam, M Shrotri, V Nguyen, I Braithwaite, S Beale, TE Byrne, ... International Journal of Infectious Diseases 123, 104-111, 2022 | 33 | 2022 |
